Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

somatostatin analogue therapy

Known as: Somatostatin Analog Therapy, therapy, somatostatin analogue 
Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors.
National Institutes of Health

Related topics

Related topics

1 relation
Hormone Therapy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first‐line somatostatin… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
OBJECTIVE In acromegaly, 25-50% of patients respond inadequately to conventional long-acting somatostatin analogue (SSA) therapy… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
We intended to identify the prognostic factors and the results of interventions on patients with liver metastatic midgut… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2007
2007
Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I…
Although the molecular mechanisms underlying GH secreting pituitary tumor formation are not well understood, mutations in the… Expand
  • figure 1
Is this relevant?
2007
2007
Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.
BACKGROUND The prevalence of gallstones (GS) is increased in acromegaly and further increased by somatostatin analogue (SA… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
CONTEXT Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly diagnosed patients with… Expand
Is this relevant?
Review
2004
Review
2004
Peptide receptor radionuclide therapy.
On their plasma membranes, cells express receptor proteins with high affinity for regulatory peptides, such as somatostatin… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1999
1999
Octapeptide somatostatin-analogue therapy of Cushing's syndrome.
The currently available octapeptide somatostatin analogues octreotide (Sandostatin, Sandostatin LAR, Novartis, Basle, Switzerland… Expand
Is this relevant?
1994
1994
Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies.
BACKGROUND/AIMS Previous studies have shown that secretory losses in patients with end jejunostomy syndrome (EJS) on home… Expand
Is this relevant?
1988
1988
Treatment of pancreatic cutaneous fistulas with a somatostatin analog.
Five pancreatic cutaneous fistulas were treated by subcutaneous administration of a long-acting synthetic analog of somatostatin… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE